Reply To: Ocrelizumab – a breakthrough?

December 16, 2021 at 12:08 am

Off-label use of ocrelizumab to treat cidp (off-label because it isn’t yet approved for CIDP by the FDA):

https://pubmed.ncbi.nlm.nih.gov/32875645